Tag Archives: pharma

The IPA and Bayh-Dole on nonprofit assignment of subject inventions, 2

We have looked at the IPA assignment clause. Since the IPA is specific to nonprofits, there’s no reason to call out nonprofitedness. But there is a reason then to restrict any later invention assignment to nonprofit assignees. Why? The point … Continue reading

Posted in Bayh-Dole, History | Tagged , , , | Comments Off on The IPA and Bayh-Dole on nonprofit assignment of subject inventions, 2

Reflections on Shill Reflections on Bayh-Dole, 7: Grubbers, innovation, and march-in

Reflections on Bayh-Dole by “industry leaders”–who are, apparently, mostly shills out shilling for (and to) the pharmaceutical industry. Good shilling earns shillings, so it is a viable career choice. We use these shills reflecting on Bayh-Dole to also reflect on … Continue reading

Posted in Bayh-Dole, Policy | Tagged , , , | Comments Off on Reflections on Shill Reflections on Bayh-Dole, 7: Grubbers, innovation, and march-in

The Purpose of Bayh-Dole: Effects

Bayh-Dole re-establishes a pipeline of patent monopolies on federally supported inventions in public health running from federal agencies to the U.S. pharmaceutical industry. This patent pipeline operates directly from federal agencies granting exclusive licenses (35 USC 207-209) and through nonprofit … Continue reading

Posted in Bayh-Dole | Tagged , , | Comments Off on The Purpose of Bayh-Dole: Effects

Who Owns Digital Learning Resources?–3

Plotkin moves on to make another good point–that “Big Pharma is the Model.” And it is–but the model is something other than the Cohen-Boyer patents that Plotkin launches into. Plotkin does not appear to recognize that Cohen-Boyer gene-splicing inventions were … Continue reading

Posted in Bayh-Dole | Tagged , , , | Comments Off on Who Owns Digital Learning Resources?–3

Bayh-Dole’s preemption of public purposes to re-establish a patent monopoly pipeline

I wrote a Twitter thread in retweeting this observation. Erin (Eeks) Stair @DrErinkate Don’t forget about Bayh-Dole, passed in the 80s, which enabled the #NIH to use our tax dollars to fund drug research at institutions & businesses; allow them … Continue reading

Posted in Bayh-Dole, History | Tagged , , , , , | Comments Off on Bayh-Dole’s preemption of public purposes to re-establish a patent monopoly pipeline

The National Patent Planning Commission argument for government-created private patent monopolies, 3

The National Patent Planning Commission quotes administration officials repeating this same argument. Here’s the Under Secretary of Agriculture (1941): The commercial exploitation of new inventions requires, in many cases, the expenditure of large sums of money. In such a case, … Continue reading

Posted in History, Innovation, Policy | Tagged , , , , | Comments Off on The National Patent Planning Commission argument for government-created private patent monopolies, 3